{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:53:01Z","timestamp":1781671981709,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024217","name":"Osaka International Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.gore.2026.102110","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:15:04Z","timestamp":1779722104000},"page":"102110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Complete remission of small cell neuroendocrine carcinoma of the cervix treated with chemotherapy of paclitaxel, carboplatin, bevacizumab and pembrolizumab: A case report"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-1142","authenticated-orcid":false,"given":"Reisa","family":"Kakubari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Nonokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ogimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Yamabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102110_b0005","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.gore.2026.102110_b0010","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2017.12.001","article-title":"A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix","volume":"148","author":"Castle","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102110_b0015","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","article-title":"Phase II trial of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract","volume":"158","author":"Frumovitz","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102110_b0020","article-title":"Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LSSCLC) receiving chemoradiotherapy (CRT)","volume":"207","author":"Gronberg","year":"2025","journal-title":"LungCancer"},{"key":"10.1016\/j.gore.2026.102110_b0025","series-title":"Global Cancer Observatory: Cancer Today","author":"International Agency for Research on Cancer","year":"2022"},{"key":"10.1016\/j.gore.2026.102110_b0030","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Ju","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gore.2026.102110_b0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/PAS.0b013e3181d1d457","article-title":"An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and p63","volume":"34","author":"McCluggage","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.gore.2026.102110_b0040","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.21873\/anticanres.16288","article-title":"Recent advances in the management of small cell carcinoma of the uterine cervix","volume":"43","author":"Miyoshi","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gore.2026.102110_b0045","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102110_b0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000506446","article-title":"Complete response of recurrent small cell carcinoma of the uterine cervix to paclitaxel, carboplatin, and bevacizumab combination therapy","volume":"13","author":"Nakao","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.gore.2026.102110_b0055","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gore.2026.102110_b0060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.gore.2026.102110_b0065","article-title":"Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis","volume":"9","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gore.2026.102110_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.1998.5248","article-title":"Molecular abnormalities associated with endocrine tumors of the uterine cervix","volume":"72","author":"Wistuba","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102110_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156146","article-title":"Immune cell densities, HLA status, and PD-L1 expression in neuroendocrine neoplasm of the uterine cervix","volume":"273","author":"Yamada","year":"2025","journal-title":"Pathol. Res. Pract."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:05:13Z","timestamp":1781669113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"alternative-id":["S2352578926000901"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102110","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complete remission of small cell neuroendocrine carcinoma of the cervix treated with chemotherapy of paclitaxel, carboplatin, bevacizumab and pembrolizumab: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102110"}}